Rigel Pharmaceuticals
RIGL
127 hedge funds and large institutions have $407M invested in Rigel Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 12 closing their positions.
131% more call options, than puts
Call options by funds: $835K | Put options by funds: $362K
33% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 33
2% more capital invested
Capital invested by funds: $400M → $407M (+$6.66M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
0.31% less ownership
Funds ownership: 9.31% → 9% (-0.31%)
3% less funds holding
Funds holding: 131 → 127 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$11.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.14M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$1.49M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.29M |
| 5 |
JP Morgan Chase
New York
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$5.59M |
| 2 |
SCM
Sio Capital Management
New York
|
-$4.14M |
| 3 |
Morgan Stanley
New York
|
-$3.95M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.59M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.89M |
RIGL Hedge Fund Activity: Q2 2019 in Review
127 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2019, worth a combined $407M — up 1.7% from $400M a quarter earlier.
Fund positioning in RIGL was balanced in Q2 2019: 12 funds opened new positions, 12 closed out, 44 added to existing stakes and 33 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $11.3M. The largest seller was Candriam SCA, exiting entirely with an estimated $5.59M sold.
- 127 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2019, down from 131 in Q1 2019.
- Funds reported $407M of Rigel Pharmaceuticals stock for Q2 2019, up 1.7% quarter-over-quarter.
- 12 funds opened new Rigel Pharmaceuticals positions in Q2 2019 and 12 closed out, a net change of 0 holders.
- The largest Rigel Pharmaceuticals buyer in Q2 2019 was Invesco, an estimated $11.3M added.
- The largest Rigel Pharmaceuticals seller in Q2 2019 was Candriam SCA, an estimated $5.59M sold.
Based on aggregated 13F filings for Q2 2019.